Indefinite Delivery Contract 75N95024D00019
Award Date
6/20/24
Last Date to Order
6/19/30
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Sri International
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Service Contract Act
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This is a multiple award indefinite delivery contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to conduct safety evaluation and toxicology studies to support drug development. The $48.6 million contract has a 6-year ordering period from June 2024 to June 2030. The contractor, IIT Research Institute (IITRI), a non-profit research organization, will perform in vitro and in vivo exploratory and...
This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $48.6 million multiple-award IDC has a 6-year ordering period from June 2024 to June 2030. The contract aims to procure safety evaluation and toxicology studies and related services to support drug development efforts at NCATS....
The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, has awarded a $48.6 million multiple-award indefinite delivery contract to conduct safety evaluation and toxicology studies in support of drug development. The contract has a 6-year ordering period and allows NCATS to issue task orders for in vitro and in vivo safety testing services, including genetic toxicology, general toxicology, and pharmacology...
The National Center for Advancing Translational Sciences (NCATS), a civilian agency, has awarded an indefinite delivery contract (IDC) worth up to $48,622,546 to Charles River Laboratories, Inc. to provide safety evaluation and toxicology studies and related services to support drug development. The contract has a period of performance from August 2024 to August 2030. Under this IDC, Charles River will perform in vitro and in vivo exploratory and Investigational New Drug (IND)-directed...
This federal contract IDV award is for CRO (Contract Research Organization) support for medicinal chemistry lead optimization programs managed by the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The prime contractor, SRI International, is a large non-profit research and development organization with a significant history of providing advanced scientific and technical...
The National Institute on Drug Abuse (NIDA), a component of the Department of Health and Human Services (HHS), awarded an Indefinite Delivery Indefinite Quantity (IDIQ) contract titled "Toxicological Evaluations of Potential Medications" to Sri International, a non-profit research and development institute. The IDIQ has a ceiling value of $9,750,000 and a 5-year ordering period from September 12, 2023 through September 11, 2028. Under this IDIQ, Sri International will conduct...
This indefinite delivery contract (IDC) was awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to the Lovelace Biomedical Research Institute. The contract has a ceiling value of $48,882,666.00 and a period of performance through August 5, 2030. The purpose of this IDC is to obtain pharmacology studies, animal model development, and related services to support NCATS' Division of Preclinical Innovation drug...
The federal contract IDV award is for Chemistry, Manufacturing, and Control (CMC) and related services to support the development of drug products for the National Center for Advancing Translational Sciences (NCATS), a civilian agency. This is a multiple award, indefinite delivery contract with a $49,885,703 ceiling value and a period of performance through July 2031. The prime contractor, Alchem Laboratories Corporation, is a for-profit pharmaceutical manufacturer that will provide a broad...
This indefinite delivery contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Sri International, a non-profit research institute. The $3.9 million contract supports NCATS' drug development programs by (1) developing and validating sensitive bioanalytical methods to quantify concentrations of novel biologics, (2) developing assays to measure anti-drug antibodies, and (3)...
The key products and services being delivered under this federal contract IDV award from the National Cancer Institute (NCI) are preclinical toxicology studies on small molecule drug candidates for cancer and other indications. The prime contractor, IIT Research Institute (IITRI), a division of the Illinois Institute of Technology, will conduct non-GLP and GLP toxicology assessments in mice and dogs to support Investigational New Drug (IND) applications. IITRI holds several significant IDIQ...